MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
13.80
+0.19 (1.40%)
Nov 26, 2025, 4:00 PM EST - Market closed

MLTX Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
41.9830.3222.3223.0121.66
Research & Development
187.22112.7731.842.0512.64
Operating Expenses
229.2143.0954.1265.0634.29
Operating Income
-229.2-143.09-54.12-65.06-34.29
Currency Exchange Gain (Loss)
0.240.040.150.33-0.07
Other Non Operating Income (Expenses)
20.9122.099.990.27-0
EBT Excluding Unusual Items
-213.29-120.96-43.98-64.47-34.37
Other Unusual Items
-----30
Pretax Income
-213.29-120.96-43.98-64.47-64.37
Income Tax Expense
0.40.280.090.040.01
Earnings From Continuing Operations
-213.7-121.24-44.08-64.51-64.37
Minority Interest in Earnings
3.22.318.0714.53-
Net Income
-210.5-118.94-36.01-49.97-64.37
Net Income to Common
-210.5-118.94-36.01-49.97-64.37
Shares Outstanding (Basic)
636349298
Shares Outstanding (Diluted)
636349298
Shares Change (YoY)
1.82%27.99%67.30%274.47%-
EPS (Basic)
-3.33-1.89-0.73-1.70-8.21
EPS (Diluted)
-3.33-1.89-0.73-1.70-8.21
Free Cash Flow
-185.9-117.11-43.06-55.91-42.27
Free Cash Flow Per Share
-2.94-1.86-0.88-1.90-5.39
EBITDA
-226.97-141.71-53.75-64.9-34.29
D&A For EBITDA
2.231.380.370.160.01
EBIT
-229.2-143.09-54.12-65.06-34.29
Updated Nov 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q